BOULDER, Colo., July 28, 2026
Ambrosia Biosciences Inc. has strengthened its leadership team and scientific capabilities with the appointment of Linda Shapiro Manning, M.D., Ph.D., FTOS, as Chief Medical Officer (CMO) and the addition of Randy Seeley, Ph.D., to its Scientific Advisory Board (SAB). The strategic appointments are designed to accelerate the company’s next-generation oral small molecule therapies for obesity and cardiometabolic diseases, reinforcing its commitment to advancing innovative treatments into clinical development. Dr. Shapiro brings nearly 30 years of clinical and research experience in obesity and cardiometabolic medicine, while Dr. Seeley is internationally recognized for his pioneering research on the gut-brain axis, obesity, and diabetes. Together, these leadership additions significantly enhance Ambrosia’s expertise in clinical development, translational medicine, and metabolic disease research, supporting the company’s mission to develop differentiated precision therapies that improve patient outcomes while reducing the complexity and cost of obesity treatment. The appointments reflect Ambrosia’s continued investment in scientific excellence as it prepares to advance its expanding pipeline toward clinical evaluation.
Experienced Clinical Leadership Accelerates Obesity Pipeline
The appointment of Dr. Linda Shapiro Manning as Chief Medical Officer represents a major milestone in Ambrosia Biosciences’ clinical development strategy. Dr. Shapiro is a recognized cardiometabolic medicine leader with nearly three decades of experience spanning both patient care and pharmaceutical research. Throughout her career, she has contributed to multiple Investigational New Drug (IND) applications, New Drug Applications (NDAs), and supplemental regulatory submissions involving GLP-1 therapies, amylin-based medicines, and other metabolic disease targets while serving in leadership positions at Novo Nordisk, Boehringer Ingelheim, and Rhythm Pharmaceuticals. In addition to her pharmaceutical expertise, she has personally treated more than 5,000 obesity patients, providing valuable real-world clinical insights that strengthen patient-centered drug development. Company leadership emphasized that her extensive regulatory experience and proven track record in obesity medicine will play a critical role in advancing Ambrosia’s highly differentiated pipeline of oral small molecule therapies into clinical studies, supporting the company’s vision of delivering transformative treatments for obesity and cardiometabolic disorders.
Scientific Advisory Board Gains Global Obesity Research Expertise
Ambrosia has also expanded its Scientific Advisory Board through the appointment of Dr. Randy Seeley, a globally respected researcher in obesity and metabolic disease. Dr. Seeley serves as the Henry K. Ransom Endowed Professor of Surgery at the University of Michigan School of Medicine and directs the NIH-funded Michigan Nutrition Obesity Research Center. His internationally recognized research focuses on the gut-brain axis, exploring how neural pathways regulate energy balance, metabolism, obesity, and diabetes. Over his distinguished career, Dr. Seeley has authored more than 400 peer-reviewed scientific publications and received numerous honors, including the American Diabetes Association Outstanding Scientific Achievement Award. His appointment strengthens Ambrosia’s scientific advisory capabilities by providing deep expertise in metabolic disease biology, translational research, and innovative therapeutic strategies. Company executives believe his scientific guidance will further support the development of novel therapies and combination approaches aimed at addressing significant unmet needs in obesity and related metabolic disorders.
Advertisement
Ambrosia Expands Innovation in Cardiometabolic Drug Discovery
Ambrosia Biosciences continues to position itself as an emerging innovator in obesity and metabolic disease drug discovery through its focus on next-generation oral small molecule therapeutics. The company integrates structure-enabled drug design, advanced medicinal chemistry, and in-house biological research capabilities to develop differentiated therapies designed to improve patient experience while expanding access to effective cardiometabolic treatments. Unlike many current obesity therapies that rely on injectable biologics, Ambrosia is advancing a complementary pipeline of orally administered precision medicines that may simplify long-term treatment and broaden patient accessibility. The appointments of Dr. Shapiro and Dr. Seeley reinforce the company’s commitment to combining world-class scientific leadership with innovative research capabilities as it advances its pipeline toward clinical development. By strengthening both executive leadership and external scientific expertise, Ambrosia Biosciences is building a strong foundation to accelerate the development of next-generation obesity therapies, expand innovation across the rapidly growing cardiometabolic medicine market, and address the increasing global demand for effective treatments targeting obesity and related metabolic diseases.
Source: Ambrosia Biosciences press release
